These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16435892)

  • 21. Estimating the number of antiretroviral treatment facilities based on the Wilson-Blower method.
    Malangu N
    PLoS Med; 2005 Aug; 2(8):e270. PubMed ID: 16120012
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparative analysis of outpatient costs in HIV treatment programs.
    Sarti FM; Nishijima M; Campino AC; Cyrillo DC
    Rev Assoc Med Bras (1992); 2012; 58(5):561-7. PubMed ID: 23090227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic models of antiretroviral therapy: searching for the optimal strategy.
    Hellinger FJ
    Pharmacoeconomics; 2006; 24(7):631-42. PubMed ID: 16802839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences.
    Rosen S; Sanne I; Collier A; Simon JL
    PLoS Med; 2005 Nov; 2(11):e303. PubMed ID: 16159308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Affordability--the forgotten criterion in health-care priority setting.
    Cleary SM; McIntyre D
    Health Econ; 2009 Apr; 18(4):373-5. PubMed ID: 19267322
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers.
    Foreman C; Gazzard B; Johnson M; Sharott P; Collins S
    Sex Transm Infect; 2012 Mar; 88(2):112-5. PubMed ID: 22345023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commitment needed from South Africa's new president.
    The Lancet Hiv
    Lancet HIV; 2018 Apr; 5(4):e155. PubMed ID: 29625673
    [No Abstract]   [Full Text] [Related]  

  • 30. South Africa's national response to HIV and AIDS treatment: popular media's perspective.
    Muula AS
    Croat Med J; 2008 Feb; 49(1):114-9. PubMed ID: 18293476
    [No Abstract]   [Full Text] [Related]  

  • 31. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paying the price for AIDS denialism.
    Bateman C
    S Afr Med J; 2007 Oct; 97(10):912-4. PubMed ID: 18000570
    [No Abstract]   [Full Text] [Related]  

  • 33. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM.
    Phillips AN; Cambiano V; Miners A; Lampe FC; Rodger A; Nakagawa F; Brown A; Gill ON; De Angelis D; Elford J; Hart G; Johnson AM; Lundgren JD; Collins S; Delpech V
    AIDS; 2015 Sep; 29(14):1855-62. PubMed ID: 26372391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating the lost benefits of antiretroviral drug use in South Africa.
    Chigwedere P; Seage GR; Gruskin S; Lee TH; Essex M
    J Acquir Immune Defic Syndr; 2008 Dec; 49(4):410-5. PubMed ID: 19186354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of different feeding patterns combined with prompt treatments for preventing mother-to-child HIV transmission in South Africa: estimates from simulation modeling.
    Yu W; Li C; Fu X; Cui Z; Liu X; Fan L; Zhang G; Ma J
    PLoS One; 2014; 9(7):e102872. PubMed ID: 25055039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The "free by 5" campaign for universal, free antiretroviral therapy.
    Whiteside A; Lee S
    PLoS Med; 2005 Aug; 2(8):e227. PubMed ID: 16008506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost and outcomes of paediatric antiretroviral treatment in South Africa.
    Meyer-Rath G; Brennan A; Long L; Ndibongo B; Technau K; Moultrie H; Fairlie L; Coovadia A; Rosen S
    AIDS; 2013 Jan; 27(2):243-50. PubMed ID: 23014517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up.
    Calmy A; Klement E; Teck R; Berman D; Pécoul B; Ferradini L
    AIDS; 2004 Dec; 18(18):2353-60. PubMed ID: 15622311
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiretroviral treatment in resource-poor settings: what can we learn from the existing programmes in Thailand?
    Phanuphak P
    AIDS; 2004 Jun; 18 Suppl 3():S33-8. PubMed ID: 15322482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
    AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.